Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Corcept Therapeutics Incorpora - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CORT
Nasdaq
2834
https://www.corcept.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Corcept Therapeutics Incorpora
Corcept Therapeutics First Quarter 2024 Earnings: Beats Expectations
- May 3rd, 2024 10:48 am
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
- May 2nd, 2024 3:45 pm
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
- May 2nd, 2024 2:48 pm
Q1 2024 Corcept Therapeutics Inc Earnings Call
- May 2nd, 2024 12:01 pm
Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
- May 2nd, 2024 7:41 am
Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024
- May 1st, 2024 9:50 pm
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- May 1st, 2024 8:05 pm
Corcept Completes Enrollment in Phase 4 CATALYST Trial
- Apr 29th, 2024 12:00 pm
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Apr 24th, 2024 8:05 pm
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
- Apr 23rd, 2024 4:12 pm
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
- Apr 22nd, 2024 12:00 pm
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
- Apr 17th, 2024 4:00 pm
Corcept (CORT) Completes Enrollment in Phase II ALS Study
- Apr 16th, 2024 3:34 pm
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Apr 15th, 2024 12:00 pm
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
- Apr 9th, 2024 3:09 pm
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
- Apr 8th, 2024 12:00 pm
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
- Apr 1st, 2024 12:00 pm
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
- Mar 29th, 2024 3:30 pm
Investing in Corcept Therapeutics (NASDAQ:CORT) five years ago would have delivered you a 114% gain
- Mar 29th, 2024 10:37 am
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
- Mar 27th, 2024 3:30 pm
Scroll